share_log

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences公司宣布,它已经在Arc-10中给第一个受试者注射了剂量,这是一个第三阶段的研究,公司说,第一个受试者的剂量将触发向药明生物和Abmuno治疗公司支付1000万美元的里程碑式的付款
Benzinga Real-time News ·  2021/03/17 04:32

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti

Arcus Biosciences公司宣布,它已经在Arc-10中给第一个受试者注射了剂量,这是一个第三阶段的研究,公司说,第一个受试者的剂量将触发向药明生物和Abmuno治疗公司支付1000万美元的里程碑式的付款

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发